Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00770731 · ClinicalTrials.gov registry record · Phase 1
Study of Temsirolimus, Topotecan, and Bortezomib
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT00770731: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00770731 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00770731, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of Torisel (temsirolimus), Hycamtin (topotecan hydrochloride), and Velcade (bortezomib) that can be given, in combination, to patients with advanced cancer that has spread or is unable to be surgically removed. The safety of this drug combination will also be studied.
Interventions
- DRUG Velcade (Bortezomib)
- DRUG Torisel (Temsirolimus)
- DRUG Hycamtin (Topotecan)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2008-09 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00770731
The ClinicalTrials.gov registry entry for NCT00770731 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Velcade (Bortezomib) is the first listed.
NCT00770731 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00770731 about?
NCT00770731 is a clinical study titled "Study of Temsirolimus, Topotecan, and Bortezomib". The goal of this clinical research study is to find the highest tolerable dose of Torisel (temsirolimus), Hycamtin (topotecan hydrochloride), and Velcade (bortezomib) that can be given, in combination, to patients with advanced cancer that has spread or is unable to be surgically removed. The safety...
What is the current status of trial NCT00770731?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2008-09. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00770731?
The interventions under investigation include: Velcade (Bortezomib) (DRUG), Torisel (Temsirolimus) (DRUG), Hycamtin (Topotecan) (DRUG).
Who is sponsoring clinical trial NCT00770731?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.